Fujian "4 plus 7" renewal when the open inquiry stage lipeone flow standard

Medical Network May 21 hearing May 19, the Fujian Provincial Medical Insurance Bureau publicity "section 4 + 7 public inquiry intends to pilot the drug selected results," Qilu Pharmaceutical of atorvastatin calcium obtained qualifications intend selected through a public inquiry risperidone sheet is bidsMay 7, Fujian Province began to follow up the implementation of "4 + 7" renewal workAccording to the rules of the renewal documents point of view, atorvastatin calcium tablets and Risperidone two varieties due to the "4 + 7" to expand around the lowest and companies do not agree to renew, expand around places no higher than the average price of expanding public inquiry Wai selected companies, to take the lowest contract"4 + 7" with a volume of a pilot in Huahaiyaoye price 10.02 yuan / cassette bid, the bid price of 7.2 yuan after / in the cartridge to expand aroundIn the "4 + 7" urban renewal process, but also to expand around Huahai prices in most cities in the fight to renew qualificationsWhile risperidone sheet "4 + 7" when there are three winningexpand around, respectively, Qilu Pharmaceutical (0.049 yuan / tablet), Changzhou four drugs (0.12 yuan / tablet), Huahai (0.12 yuan /sheet)Qilu Pharmaceutical successful bidder in atorvastatin calcium public inquiry process, but abandoned the renewal qualifications risperidone tablets, resulting risperidone public inquiry in mid-stream standardAccording to the rules of renewed Fujian Province, no enterprise should be marked at the public inquiry, in order to expand around the selected price from low to high ranked second, third enterprises by the enterprise to expand around were selected price inquiryFollow-up results may be announced shortly.